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Effect of ritonavir on the pharmacokinetics of the
benzimidazoles albendazole and mebendazole: an interaction
study in healthy volunteers
Abstract
BACKGROUND: Benzimidazoles are often used concomitantly with protease inhibitors in patients with
helminthic disease and HIV infection. Low bioavailability and extensive first-pass metabolism make
benzimidazoles prone to pharmacokinetic drug interactions. The aim of the present study was to
investigate potential drug interactions between the benzimidazoles albendazole and mebendazole and
the potent CYP3A4 inhibitor ritonavir. METHODS: Sixteen healthy volunteers were administered a
single oral dose of 1,000 mg mebendazole or 400 mg albendazole (2 x n = 8). AUC, C(max), and t(1/2)
of mebendazole, albendazole, and albendazole sulfoxide were studied in absence and after short-term (2
doses) and long-term (8 days) treatment with ritonavir 200 mg bid. RESULTS: Pharmacokinetic
parameters of albendazole and mebendazole were not changed by short-term administration of ritonavir.
However, long-term administration of ritonavir resulted in significant changes in albendazole and
mebendazole disposition, with a significant decrease in AUC(0-24) (27 and 43% of baseline for
albendazole and mebendazole, respectively) and C(max) (26 and 41% of baseline, respectively).
CONCLUSION: The AUC(0-24) of benzimidazoles decreased after long-term use of ritonavir, while no
changes in pharmacokinetic profiles were observed under short-term administration. These findings
might help to optimize benzimidazole efficacy when used in combination with protease inhibitors.
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ABSTRACT 
Background: Benzimidazoles are often used concomitantly with protease inhibitors in 
patients with helminthic disease and HIV infection. Low bioavailability and extensive first 
pass metabolism make benzimidazoles prone to pharmacokinetic drug interactions. The aim 
of the present study was to investigate potential drug interactions between the benzimidazoles 
albendazole and mebendazole and the potent CYP3A4 inhibitor ritonavir. Methods: Sixteen 
healthy volunteers were administered a single oral dose of 1000mg mebendazole or 400mg 
albendazole (2 x n=8). AUC, Cmax and T1/2 of mebendazole, albendazole and albendazole 
sulfoxide were studied in absence and after short term (2 doses) and long term (8 days) 
treatment with ritonavir 200mg bid. Results: Pharmacokinetic parameters of albendazole and 
mebendazole were not changed by short term administration of ritonavir. However, long-term 
administration of ritonavir resulted in significant changes in albendazole and mebendazole 
disposition, with a significant decrease in AUC0-24 (27% and 43% of baseline for albendazole 
and mebendazole, respectively) and Cmax (26% and 41% of baseline respectively). 
Conclusion: Benzimidazoles AUC0-24 decreases after long-term use ritonavir, while no 
changes in pharmacokinetic profiles are observed under short-term administration. These 
findings might help to optimize benzimidazoles efficacy when used in combination with 
protease inhibitors. 
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INTRODUCTION 
Albendazole and mebendazole are benzimidazoles used for the therapy of various helminthic 
infections as well as for the treatment of hydatid disease (Echinococcus granulosus) and 
alveolar echinococcosis (Echinococcus multilocularis) [1]. Combination of benzimidazoles 
with anti-HIV medications such as protease inhibitors is increasingly used in developing 
countries, where both, helminthic disease and HIV infection are endemic [2]. While HIV 
therapy is not affected by co-administration of benzimidazoles [2], no data are so far available 
on the effect of protease inhibitors on antiparasitic treatment. However low bioavailability 
and extensive first pass metabolism make benzimidazoles especially prone to 
pharmacokinetic drug interactions, and dose-related toxicity could therefore arise in 
combination with potent inhibitors of benzimidazoles metabolism. In line with these 
concerns, a metabolic drug interaction was recently suggested as underlying 
pathophysiological mechanism of a case of severe dose-related hematological toxicity 
described under comedication of albendazole and mebendazole with the protease inhibitors 
ritonavir and nelfinavir [3]. 
After oral administration, albendazole and mebendazole are poorly absorbed in the intestinal 
tract, mainly due to limited solubility [4]. Furthermore, benzimidazoles undergo extensive 
intestinal and hepatic bioconversion, adding to the low systemic exposures with these 
compounds [5, 6]. In case of albendazole, different cytochrome P450 enzymes (CYP) and the 
flavine-containing monooxygenase (FMO) system seem to be responsible for intestinal and 
hepatic sulfoxidation of the parent compound to albendazole sulfoxide [6, 7], while CYP1A2 
is involved in sulfonidation [8]. Formation of albendazole-sulfoxide is stereoselective with 
CYP3A4 being the key player in the formation of (-)-albendazole sulfoxide, whereas 
formation of (+)-albendazole sulfoxide is mediated by the FMO system [7]. In line with these 
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observations, co-administration of potent CYP3A4 inhibitors such as cyclosporine or 
ketoconazole were associated with increased albendazole plasma levels in different animal 
models, which was interpreted as a result of inhibited intestinal elimination of albendazole 
[9]. Furthermore, the non-selective cytochrome P450 inhibitors clotrimazole and the FMO-
inhibitor methimazole significantly inhibited albendazole metabolism in rat liver microsomes 
[7]. In contrast, only few data are available on specific enzymes involved in the metabolism 
of mebendazole. Metabolites isolated from feces and urine as well as results of the 
aminopyrine breath test suggest the involvement of a keton reductase and different CYP 
isoforms [10, 11]. Furthermore, interaction data in healthy volunteers indicate that the non-
specific cytochrome P450 (CYP) inhibitor cimetidine significantly increases mebendazole 
plasma levels [10, 12], pointing towards an involvement of cytochrome P450 enzymes in 
mebendazole metabolism. 
The protease inhibitor ritonavir is among the most potent inhibitors of the CYP3A system 
[13]. Consequently, interaction of protease inhibitors with drugs that are cleared 
predominantly by CYP3A enzymes are profound and clinically significant [14]. It is still 
equivocal whether long-term administration of ritonavir may also lead to a certain induction 
of CYP3A enzymes [15]. However, studies both in healthy volunteers [16] and patients [17] 
do not support CYP3A4 induction. 
Given the lack of systematic data on the disposition and interaction of benzimidazoles with 
protease inhibitors the aim of the present study was to investigate potential drug interactions 
between the benzimidazoles albendazole and mebendazole and ritonavir under single dose 
and steady state conditions. The protease inhibitor ritonavir was chosen as model inhibitor, 
because of its anticipated use in combination with benzimidazoles and its reported association 
with dose-related toxicity of albendazole and mebendazole. Furthermore the effect of long 
term administration of ritonavir on benzimidazole metabolism was investigated.  
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METHODS 
Patients and study design 
After approval of by local ethics committee and written informed consent 16 healthy, 
nonsmoking, HIV-negative male Caucasian volunteers were included in the study. All 
participants had to be healthy as confirmed by physical examination and routine laboratory 
screening of hematological and clinical-chemical parameters, including renal, hepatic and 
pancreatic parameters. None of the participants took any regular medication, and all abstained 
from alcohol for the duration of the study. Because of possible gender-related differences in 
the pharmacokinetic profiles of albendazole metabolites [18], only male volunteers were 
included. 
The study was performed at the Clinical Research Unit of the University Hospital Zürich. To 
minimize food associated variability in absorption, study medication was administered after 
an overnight fast. Volunteers were given a single oral dose of 1000 mg mebendazole 
(Vermox® tablets 500mg, Janssen-Cilag, Baar Switzerland) (n=8 individuals) or of 400 mg 
albendazole (Zentel® tablets, GlaxoSmithKline, Münchenbuchsee, Switzerland) (n=8 
individuals). Mebendazole and albendazole were taken in the morning of three independent 
days (day 1, 8 and 15) with 100 ml water. Oral ritonavir 200 mg bid (Norvir® 100mg 
capsules, Abbott, Baar, Switzerland) was started in the evening of day 7 and was continued 
until the morning of day 15. Standardized breakfast and lunch were served after the 2 hour 
and the 4 hour blood samples.  
Pharmacokinetic profiles of albendazole and mebendazole were performed on day 1 
(baseline), day 8 (after 2doses of ritonavir) and day 15 (long term ritonavir). Blood samples 
for the analysis of albendazole and mebendazole were drawn from a venous line before and 
after 30 minutes, 1, 2, 3, 4, 6, 10 and 24 hours after the benzimidazole administration. 
Ritonavir samples were taken once in the morning of day 8 and 15 for compliance control. All 
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blood samples were immediately centrifuged at 4° C and the plasma stored at - 20° C until 
further analysis.  
 Study participants were allowed to leave the trial unit on the evenings of day 1, 8 and 15 and 
returned for the 24 hour sample on the following morning. On the last pharmacokinetic day 
(day 15), a liver, pancreatic and renal panel was determined for safety reasons.  
 
Analysis of albendazole and mebendazole 
Plasma concentrations of albendazole, its active metabolite albendazole-sulfoxide, 
mebendazole and ritonavir were measured at the Institute of Clinical Chemistry, University 
Hospital Zurich. Albendazole, albendazole sulfoxide and mebendazole with flubendazole as 
internal standard (IS) were determined by liquid chromatography tandem mass spectrometry 
with positive atmospheric pressure chemical ionization (LC-MS/MS). The different 
benzimidazoles were separated with reversed-phase chromatography using a gradient system 
of ammoniumformiate buffer pH3, methanol and acetonitrile. 1 ml of plasma was extracted 
by solid phase extraction using C18-columns. Elution was performed with 2 ml methanol 
containing 2.5% dimethyl sulfoxide. achieved using selected reaction monitoring (SRM) of 
the transitions of m/z 266 → 234 for albendazole, m/z 282 →  240 for albendazole sulfoxide, 
m/z 296 →  264 for mebendazole and m/z 314 → 282 for the IS. 
The standard curves were plotted as the peak area ratio of the respective benzimidazole to the 
internal standard. To assess linearity, the best fit was determined by least square regression. 
The accuracy of the method was 103% for albendazole, 102% for albendazole sulfoxide, and 
101% for mebendazole, respectively. The coefficients of variation within one day and 
between different days were < 10% for all analytes. 
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Pharmacokinetic analysis 
Changes in albendazole and mebendazole pharmacokinetics were evaluated under 
concomitant short term (day 8) and long term (day 15) intake of ritonavir. The maximum 
plasma concentration (Cmax) and the time of occurrence of Cmax (Tmax) were taken from 
concentration time curves. Plasma concentrations of albendazole, albendazole sulfoxide and 
mebendazole were plotted semi logarithmically against time, and the AUC was calculated by 
the trapezoidal rule for the periods from 0 to 24 hours. The apparent terminal half-life (T1/2) 
was estimated by non-compartmental analysis using the pharmacokinetic software WinNonlin 
Version 5.0. (Pharsight Corp., Cary, NC).  
 
Power calculation 
The aim of this study was to compare pharmacokinetic profiles of albendazole and 
mebendazole under concomitant short term and long term administration of the CYP3A4 and 
P-glycoprotein inhibitor ritonavir. Changes in AUC0-24 and Cmax were chosen as primary 
endpoints. Sample size calculation was based upon the following considerations: (i) the extent 
of interindividual variability in albendazole pharmacokinetics in healthy volunteers [4], (ii) 
The extent of interindividual variability of multiple dose oral ritonavir pharmacokinetics in 
healthy volunteers [19], (iii) the observed increase of simvastatin AUC in an interaction 
studies with ritonavir [20], as simvastatin exhibits a bioavailability comparable to that of 
mebendazole and albendazole and (iv) the observed increase in mebendazole plasma 
concentrations under co-treatment with ritonavir in a single case observation [3]. While the 
expected increase in Cmax and AUC of benzimidazoles is about 20-fold under short term use 
of ritonavir, the increase is expected to level off to about 4-fold under long-term use. Eight 
individuals per group are required to detect this 4-fold increase from baseline kinetics with a 
power of 80% and a significance level of 0.05.  
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Data analysis 
Primary parameters for the assessment of an interaction were the AUC0-24 and the Cmax of the 
three analytes (multiplicative models applied), while Tmax and t1/2 were additionally 
investigated. The interaction was handled as a bioequivalence problem [21]. The effect of 
short-term and long-term administration of ritonavir on the pharmacokinetics of mebendazole, 
albendazole and albendazole sulfoxide was evaluated. Point estimates and the corresponding 
90% confidence intervals of the two geometric mean ratios of the pharmacokinetic parameters 
in the study periods with ritonavir over those without ritonavir were calculated. An interaction 
was accepted to be present if the 90% confidence interval around the geometric mean ratio 
was entirely outside the accepted reference range of 0.80-1.25. 
 
 
 
RESULTS 
Study participants and safety 
Sixteen healthy male volunteers were enrolled in this study, eight in the albendazole and eight 
in the mebendazole arm. The mean age of study participants was 31 years (range 20 to 
46years) and the mean weight was 73kg (range 60 to 101kg). All volunteers successfully 
completed the study. Two of the participants complained about slight diarrhea while taking 
ritonavir, which reversed without sequelae. No serious adverse events occurred.  
 
Albendazole and mebendazole kinetics 
Individual pharmacokinetic parameters showed high interindividual variability: individual 
albendazole and albendazole sulfoxide AUC0-24 values differed more than twenty fold and 
mebendazole AUC0-24 values differed more than 7 fold on the first pharmacokinetic day 
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(Figure 1a-c). Outliers with excessively high AUC0-24 and Cmax values were seen in single 
individuals (individual 3 for albendazole, due to double peaked plasma concentration time 
curves, and individual 9 for mebendazole; data not shown). The pharmacokinetics of 
albendazole, its metabolite albendazole sulfoxide and mebendazole were not significantly 
changed by the administration of short term ritonavir as the 90% confidence interval of AUC0-
24 and Cmax overlapped the bioequivalence criteria (0.80-1.25) (Table 1a-c). Apart from 
individual 3 with a strong decrease of albendazole and albendazole sulfoxide AUC on the 
second PK-day after intake of 2 doses of ritonavir (Fig. 1b and 1c) only minimal changes in 
individual albendazole and albendazole sulfoxide AUC0-24 values were seen in the remaining 
study participants. The trend toward a decrease in the AUC0-24 mean value in the albendazole 
group on the second PK-day is probably due to the AUC0-24 outliers on the first PK-day. In 
the mebendazole group, a trend towards an increase in mebendazole exposure after short term 
intake of ritonavir was seen. Four of 8 participants (individuals 10, 12, 15 and 16) had an 
increase of mebendazole exposure by 30% to 80%, while 3 individuals exhibited hardly any 
change in exposure, and in one individual AUC0-24 decreased by 35%.  
However, administration of ritonavir for one week resulted in significant changes in 
albendazole and mebendazole disposition, with a significant decrease in AUC0-24 and Cmax 
compared to baseline values (Table 1a-c and Figures 2a-c). Mebendazole AUC0-24 and Cmax 
were reduced to 0.43 and 0.41 (geometric mean ratio) of baseline values, respectively, while 
albendazole and albendazole sulfoxide AUC0-24 and Cmax were reduced to 0.27 and 0.26 and to 
0.41 and 0.52 respectively. The confidence intervals of the geometric mean ratios were 
outside the bioequivalence criteria, so that an interaction had to be accepted as present. This 
was also true, when geometric mean ratios were recalculated without the outliers for both 
groups, i.e. individual 3 and individual 9 for albendazole (GM ratios AUC0-24 :0.30 [0.14-
0.60] and Cmax: 0.26 [0.09-0.70]and mebendazole  (GM ratios AUC0-24 :0.45 [0.29-0.69] and 
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Cmax: 0.45 [0.28-0.72], respectively. Only the GM ratios for albendazole sulfoxide slightly 
overlapped the bioaequiavlence criteria for the AUC (GM ratios AUC0-24 :0.57 [0.34-0.95] 
and Cmax: 0.43 [0.27-0.68]. At the same time, Tmax and the terminal half life did not change 
significantly. In all individuals ritonavir was detected in the plasma on the second and the 
third PK-day with concentrations ranging from 0.14 to 10mg/l. In two individuals in the 
mebendazole group that complained about slight diarrhea between the second and the third 
PK-day, AUC0-24 dropped by 70% on the third PK-day. A diminished absorption of 
mebendazole caused by an increased intestinal activity can therefore not fully be excluded in 
these particular cases. 
 
 
DISCUSSION 
In the present study we investigate the effect of short and long-term administration of 
ritonavir on the disposition of the benzimidazoles albendazole and mebendazole in healthy 
volunteers. As expected from previous data on oral albendazole and mebendazole disposition 
[4, 12] high interindividual variability in bioavailability was seen. While single dose 
administration of the potent CYP3A inhibitor ritonavir did not result in changes in 
albendazole and mebendazole plasma concentrations in most of the patients, long term 
administration led to a significant decrease in benzimidazoles systemic exposure.  
Inhibition of albendazole and mebendazole metabolism under co-administration of ritonavir 
has been expected based upon the low oral bioavailability of these drugs and evidence for an 
important contribution of cytochrome P450 enzymes to in-vitro metabolism [22]. While the 
relative contribution of different CYP enzymes has not been identified for mebendazole, 
CYP3A seems to be one of the key players for albendazole biotransformation [7]. However, 
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albendazole has been classified as high-clearance drug, with hepatic metabolism being 
essentially flow-limited [22].  
On the other hand, significant drug interaction after oral administration can still arise at the 
level of intestinal drug absorption, where metabolizing enzymes and transporter systems 
expressed in small intestinal enterocytes represent an important first presystemic barrier. 
Recent evidence points towards an involvement of the breast cancer resistance protein BCRP 
(ABCG2) in this process, while MDR1 P-glycoprotein, which could potentially be inhibited 
by ritonavir is not involved in benzimidazole transport [23]. Overall, flow-limited hepatic 
metabolism and predominant intestinal clearance by BCRP would explain the observation that 
albendazole disposition is not affected by intake of two doses of ritonavir.  
In contrast, ritonavir is an inducer of several phase I and phase II enzymes and transporters 
[24]. in a dose-dependent manner. A 12% decrease of ritonavir exposure is already seen with 
doses of 400mg daily and exposure further decreased by 45% with ritonavir 1000mg/d [19] 
An increase of cytochrome 2C9, 2C19 and 1A2 activity by ritonavir was shown in human 
hepatocytes [15] as well as under long term treatment with lopinavir boosted with 200mg 
ritonavir daily in healthy volunteers [16]. As CYP2C9 and CYP1A2 are involved in 
albendazole and albendazole sulfoxide metabolism [22], their induction by long term ritonavir 
administration of 400mg daily could explain a lower bioavailability of albendazole. 
Accordingly, a partial involvement of CYP2C and CYP1A2 enzymes in mebendazole 
metabolism could be postulated as an even more pronounced reduction of mebendazole was 
noted in our study. Induction of phase II enzymes could represent an alternative explanation 
as the CYP-system is only partially involved and mebendazole-conjugates are excreted as 
metabolites [11]. Ritonavir induces UDP-glucuronosyltransferase 1A1 (UGT1A1) in vitro 
[25] and plasma-concentrations of substances mainly conjugated by UGT like lamotrigine are 
markedly reduced by ritonavir co-administration [26].  
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Intraindividual variability due to poor and variable absorption of the low  water-soluble drugs 
albendazole and mebendazole might also have contributed to the observed reduction in 
exposition. Albendazole and mebendazole absorption is increased by fatty meals [4], and a 
pH-dependency has been postulated for albendazole absorption [27]. To evaluate the 
importance of variability in intestinal absorption on our findings, data were recalculated 
without the outliers with the highest AUC-values in the albendazole group (individual 3) and 
the mebendazole group (individual 9). Even by excluding these individuals from our analysis, 
decrease in AUC and Cmax for albendazole and mebendazole after long term ritonavir 
administration did still not meet the bioequivalence criteria, pointing towards a mechanism 
other than differences in drug absorption to be responsible for our observations. The slight 
overlap with the bioequivalence criteria of the albendazole metabolite is unlikely to be 
primarily due to differences in intestinal absorption. Furthermore, as no differences in Cmax 
and AUC values were observed between individuals with and without diarrhea, changes in 
gastrointestinal motility was not considered to be the main reason for the overall decrease of 
albendazole and albendazole sulfoxide AUC under long term ritonavir intake.  
Several conclusions can be drawn from this study: First, CYP3A and P-glycoprotein 
inhibition by ritonavir does not affect albendazole or mebendazole disposition, and there 
should be no concern about dose-related benzimidazoles toxicity when using combination 
therapies with protease inhibitors. Furthermore, with some caution, these observations can be 
extrapolated to other drugs known to inhibit CYP3A or P-glycoprotein, which very probably 
can safely be co-administered in patients with helminthic disease. Second, as BCRP seems to 
be a determinant of intestinal elimination of albendazole metabolites, inhibition or induction 
of this efflux process might potentially result in drug interactions. However, the in-vivo 
significance of BCRP inhibition remains to be determined and seems to be insignificant in the 
case of ritonavir. And third, long term use of this combination results in decreased exposure 
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of albendazole and mebendazole and might therefore affect treatment efficacy. This effect is 
most probably not only due to a ritonavir-mediated induction of metabolizing enzymes or 
transporters but could be related to low intestinal absorption and changes in gastrointestinal 
function.  
However, although our data help to mechanistically understand the effect of ritonavir on 
benzimidazole metabolism and transport, they do not reflect the clinical treatment reality of 
HIV infected patients, where ritonavir is almost never given as single protease inhibitor but as 
part of a combination therapy. The effect of boosted protease inhibitor combinations such as 
lopinavir/ ritonavir or atazanavir/ ritonavir, which are components of standard drug regimens 
in HIV patients, on mebendazole and albendazole kinetics, can therefore not definitely be 
deduced from our study. Furthermore, depending on whether benzimidazoles are given to 
treat intestinal or systemic parasites, a decrease in systemic bioavailability might be 
considered even an advantage, if intestinal drug levels were increased. However, suggestions 
concerning therapeutic drug monitoring for the treatment of patients with HIV and 
echinococcus co-infection cannot be given to date, since no concentration ranges to avoid 
toxicity or optimize efficacy have been established. 
 
In conclusion, our data show that benzimidazoles exposure decreases after long-term use of 
ritonavir, while no significant changes in pharmacokinetic profiles are observed under short-
term administration. These results are important for the safe and effective administration of 
these substances in certain areas of the world and should be tested for their clinical 
significance to optimize benzimidazoles efficacy when used in combination with protease 
inhibitors. 
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TABLES 
 
 
Table 1a-c    Pharmacokinetic parameters of mebendazole, albendazole and albendazole sulfoxide before and after treatment with ritonavir in 8 
 healthy volunteers 
 
 
Table 1a Pharmacokinetic parameters of mebendazole after short term (two doses) and long term (8 days) ritonavir treatment 
 
   mebendazole   
before ritonavir  short term ritonavir  long term ritonavir 
§mean ± SD  §mean ± SD 
 ¥ geometric 
mean ratio 
90% confidence 
interval of GM-
ratios 
 §mean ± SD 
 ¥ geometric 
mean ratio 
90% confidence 
interval of GM-
ratios 
AUC0-24 (µg·h/l) 207.2 ± 157.6  228.9 ± 147  1.17 0.81 - 1.70  85.9 ± 53.2 0.43 0.30 - 0.62 
Cmax (µg/l) 31.0 ± 26.0  36.0 ± 22.8  1.18 0.79 - 1.80  11.5 ± 6.2 0.41 0.27 - 0.63 
Tmax (h) 2.1 ± 1  2.4 ± 1.7     2.1 ± 0.8   
terminal  t 1/2  (h) 7.4 ± 2.2  9.3 ± 3.5    10.6 ± 8.6   
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Table 1b Pharmacokinetic parameters of albendazole after short term (two doses) and long term (8 days) ritonavir treatment 
 
 
 
   albendazole   
 before ritonavir  short term ritonavir  long term ritonavir 
 §mean ± SD  §mean ± SD 
¥ geometric 
mean ratio 
90% confidence 
interval of GM-
ratios 
 §mean ± SD 
¥ geometric 
mean ratio
90% confidence 
interval of GM-
ratios 
AUC0-24 (µg·h/l) 100.1 ± 110.8  56.6 ± 28.1 0.83 0.42 - 1.61  23.6 ± 20.7* 0.27 0.14 - 0.52 
Cmax (µg/l) 15.3 ± 10.3  16.0 ± 9 1.24 0.52 - 2.95  4.9 ± 5.2* 0.26 0.11 - 0.62 
Tmax (h) 2.1 ± 1.1  1.8 ± 1.1    2.3  ± 1.8   
terminal  t 1/2  (h) 10.2 ± 10.2  10.1  ± 7.3    17.3 ± 15.5   
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Table 1c Pharmacokinetic parameters of albendazole sulfoxide after short term (two doses) and long term (8 days) ritonavir treatment 
 
 
 
   albendazole sulfoxide  
 before ritonavir  short term ritonavir  long term ritonavir 
 §mean ± SD  §mean ± SD 
 ¥ geometric 
mean ratio 
90% confidence 
interval of GM-
ratios 
 §mean ± SD 
 ¥ geometric 
mean ratio 
90% confidence 
interval of GM-
ratios 
AUC0-24 (µg·h/l) 5441.3  ± 4725.2   3299.8 ± 1249.8  0.77 0.50 - 1.20  2354.0  ± 1896.6 0.41 0.26 - 0.65 
Cmax (µg/l) 453.9 ± 398.7   273.3 ± 119.6  0.79 0.50 - 1.26  230.9 ± 151.4 0.52 0.32 - 0.83 
Tmax (h) 4.1 ± 3.6  2.9 ± 2.0    3.6 ± 3.1   
terminal  t 1/2  (h) 17.3 ± 13.6  13.2 ± 5.6    8.9 ± 4.6   
 
 
§ arithmetic mean     
GM: geometric mean     ¥ ratio of geometric means (GM) of values under short respectively long term ritonavir treatment to values before treatment with ritonavir  
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FIGURE LEGENDS 
 
Figure 1a-c 
Individual AUC0-24 on different pharmacokinetic days of (a) mebendazole (b) albendazole, 
(c) albendazole-sulfoxide. The horizontal lines represent mean values.   
 
Figure 2a-c 
Serum concentration time curves on different pharmacokinetic days of (a) mebendazole 
(b) albendazole, (c) albendazole-sulfoxide. Baseline values (day 1) are represented by black 
circle, short-term ritonavir by white circles and long term ritonavir by triangles. Error bars 
represent standard deviation 
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